Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001422848-25-000022·ALNYLAM PHARMACEUTICALS, INC.
Schedule 13G ownership disclosure
ALNYLAM PHARMACEUTICALS INC COM
Common Stock · CUSIP: 02043Q107
Event date: 2024-12-31
- Filing-level shares
- 6,968,513.00
- Percent of class
- 5.4%
- Capital Research Global Investors
Shares: 6,968,513.00 · Class: 5.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001422848-25-000022
- Form type
- SCHEDULE 13G
- Filer
- ALNYLAM PHARMACEUTICALS, INC.
- CIK
- CIK 1178670
- Filed
- Feb 13, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership